Loading…
Genetic testing company specializing in exome and genome sequencing to diagnose rare pediatric and hereditary diseases.
Genetic testing company specializing in exome and genome sequencing to diagnose rare pediatric and hereditary diseases.
Is paid per test, mostly by insurers and Medicaid programmes, so payer coverage of exome and genome sequencing in children drives volume and price. It is the former Sema4, which narrowed to the GeneDx rare-disease unit and took its name in 2023.
Moat: narrow (data, IP / patents, scale). Large proprietary rare-disease genomic database improves diagnostic yield versus smaller testing labs.
Headquarters: Stamford, Connecticut · Founded: 2000 · Employees: 1,300
Size GeneDx (WGS) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.86B, the 1847th largest of 3,117 United States companies the cockpit tracks. Shares closed at $62.37 on 6 Nov 2026.
Performance Over six months the shares gained 53.0%, against +22.8% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 25.4% over the last twelve months (peer median +2.9%); the operating margin is -12.5% (peer median 6.7%).
Valuation It trades at 98.7× forward earnings against a peer median of 35.9× (2nd most expensive of 17).
Capital Return on invested capital runs 30.2 points below its cost of capital (14.2% WACC).
Short interest Short interest is 20.2% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $454M | $428M | $305M | $203M | $235M |
| Revenue growth | — | +40% | +51% | -14% | — |
| Gross profit | $295M | $278M | $176M | $60.6M | -$54.7M |
| EBITDA | -$29.9M | $13.4M | $492,000 | -$128M | -$355M |
| Net income | -$106M | -$21.0M | -$52.3M | -$176M | -$549M |
| Free cash flow | -$75.8M | $14.3M | -$34.0M | -$185M | -$326M |
| Capital expenditure | $27.1M | $19.0M | $5.49M | $5.71M | $14.3M |
| Total debt | $167M | $113M | $117M | $120M | $77.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GeneDx WGS | $1.86B | +53% | +25% | -12% | 98.7× | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | n/a | n/a |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% |
| Quest Diagnostics DGX | $28.1B | +36% | +9% | 15% | 22.0× | 6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WGS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.9% | +8.0% | 2nd lowest of 21 |
| 6-month return | +53.0% | +22.8% | 6th highest of 21 |
| Distance from 52-week high | -63.5% | -15.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +25.4% | +2.9% | 2nd highest of 21 |
| Operating margin | -12.5% | 6.7% | 2nd lowest of 21 |
| Forward P/E | 98.7× | 35.9× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -30.2 pp | -3.1 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |